Effect of Haemodialysis on the Efficacy of Antiplatelet Agents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-11-10

Study Completion Date

2019-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of our study is to investigate whether haemodialysis itself affects the efficacy of antiplatelet drugs and the effects of two different types of dialysis membranes (polysulfone membranes and polyamide membranes) on antiplatelet efficacy. A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after two times of haemodialysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ONSET and OFFSET of Ticagrelor in ESRD

NCT02163954

Chronic Kidney Disease

COMPLETED PHASE3

Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS

NCT02048228

CLOPIDOGREL, POOR METABOLISM of (Disorder)

UNKNOWN PHASE2/PHASE3

Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor

NCT03039205

Platelet Aggregation Adenosine Coronary Artery Disease +2 more

COMPLETED PHASE2

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

NCT03150667

Chronic Kidney Diseases Acute Coronary Syndrome

UNKNOWN PHASE4

the Effect Between Platelet Reactivation and Antiplatelet Drugs

NCT02198053

Drug Effect Disorder Platelet Procoagulant Activity Deficiency

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Failure Coronary Artery Disease Hemolysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clopidogrel

clopidogrel 75mg qd;aspirin 100mg qd, n=30

Clopidogrel group;Ticagrelor group

Intervention Type DEVICE

A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.

Ticagrelor

ticagrelor 90mg bid; aspirin 100mg qd, n=30

Clopidogrel group;Ticagrelor group

Intervention Type DEVICE

A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clopidogrel group;Ticagrelor group

A total of 60 patients with ESRD and under dual-antiplatelet treatmen for at least 5 days will be enrolled and divided into the Clopidogrel group (clopidogrel 75mg qd;aspirin 100mg qd, n=30) and the Ticagrelor group (ticagrelor 90mg bid; aspirin 100mg qd, n=30). All included patients will receive haemodialysis by two different types of dialysis membrane.Platelet aggregation of venous blood from all patients will be detected by LTA and VerifyNow immediately before and after haemodialysis.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of coronary heart disease including stable angina, unstable angina, acute myocardial infarction
* taking dual antiplatelet drugs (clopidogrel 75mg qd + aspirin 100mg qd or ticagrelor 90 mg,bid + aspirin 100 mg,qd) at least 5 days
* haemodialysis patients
* sign informed consent

Exclusion Criteria

* platelet count\>450 × 10 9 /L or \<100 × 10 9 /L
* using IIb / IIIa inhibitor drugs within 10days
* taking nonsteroidal anti-inflammatory drugs other than aspirin
* hemorrhagic disease
* allergic to aspirin, ticagrelor or clopidogrel
* other factors may affect the results of this study

Eligible Sex

ALL

Accepts Healthy Volunteers

No